Edward Romond
Edward Romond, University of Kentucky, Lexington
More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding trastuzumab to doxorubicin and cyclophosphamide followed by paclitaxel.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.